Literature DB >> 9928770

Problems of long-term spinal opioid treatment in advanced cancer patients.

Sebastiano Mercadante1.   

Abstract

Epidural and intrathecal techniques are well established techniques in cancer pain. However, several questions remain unresolved. The several problems of long-term spinal opioid treatment in advance cancer patients were reviewed. Indications for the use of spinal opioids include patients treated by systemic opioids with effective pain relief but with unacceptable side effects, or unsuccessful treatment with sequential strong opioid drug trials despite escalating doses. Therefore, the previous aggressive treatment with systemic opioids would leave as failures patients with difficult pain syndromes unresponsive to opioids. The choice of external or totally implanted delivery systems is based on different clinical considerations. The use of externalized tunneled intrathecal catheters has not been associated with higher rates of complications and is easier to place and use at home in debilitated patients late in the course of their disease. The intrathecal administration has a lower incidence of catheter occlusion, lower malfunctioning rate, lower dose requirement, and more effective pain control. Due to the lower daily doses and volumes, intrathecal treatment proved to be more suitable for treatment at home by a continuous infusion than the epidural treatment. Advantages of infusion techniques are more evident when using local anesthetics, since intermittent administration of bupivacaine often results in motor paralysis and hemodynamic instability. Morphine is the opioid of choice. An epidural dose of 10% of the systemic dose is often used. However, intrathecal administration of opioids and bupivacaine may substantially improve pain relief in patients unresponsive to high epidural doses of these drugs, Bupivacaine-induced adverse effects, including sensory deficits, motor complaints, signs of autonomic dysfunction or neurotoxicity have been reported to not occur with bupivacaine doses less than 30-60 mg/day. Adjuvant drugs may further improve analgesia. Different ranges of technical complication rates have been reported in the literature, most of them being associated with epidural catheters. Subcutaneous tunneling and fixation of the catheter, bacterial filters, minimum changes of tubings, careful exit site care weekly, site protection and monitoring of any sign of infection to prevent infection, and training for family under supervision, are recommended. Areas for additional research include the use of spinal adjuvants, the ideal spinal morphine-bupivacaine ratio. methods to improve spinal opioid responsiveness and long-term catheter management with appropriate home care programs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9928770     DOI: 10.1016/S0304-3959(98)00118-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  Dialogues on complex analgesic strategies for difficult pain syndromes.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera
Journal:  Support Care Cancer       Date:  2004-04-09       Impact factor: 3.603

Review 2.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  [Palliative therapy in bronchial carcinoma--implanted delivery system and ports].

Authors:  Thomas Reif-Gintl; Wilfried Ilias
Journal:  Wien Med Wochenschr       Date:  2008

Review 4.  Malignant bone pain: pathophysiology and treatments.

Authors:  C Ripamonti; F Fulfaro
Journal:  Curr Rev Pain       Date:  2000

5.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

6.  Validation of a preclinical spinal safety model: effects of intrathecal morphine in the neonatal rat.

Authors:  B David Westin; Suellen M Walker; Ronald Deumens; Marjorie Grafe; Tony L Yaksh
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

Review 7.  Intrathecal drug delivery for chronic pain management-scope, limitations and future.

Authors:  M Czernicki; G Sinovich; I Mihaylov; B Nejad; S Kunnumpurath; G Kodumudi; N Vadivelu
Journal:  J Clin Monit Comput       Date:  2014-08-31       Impact factor: 2.502

8.  Intrathecal analgesia and palliative care: a case study.

Authors:  Naveen S Salins; Gregory B Crawford
Journal:  Indian J Palliat Care       Date:  2010-01

Review 9.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08

10.  Intrathecal infusions for intractable cancer pain: a qualitative study of the impact on a case series of patients and caregivers.

Authors:  Philippa Hawley; Elizabeht Beddard-Huber; Cameron Grose; William McDonald; Daphne Lobb; Louise Malysh
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.